467
edits
Cardiac Pharmacology: Difference between revisions
no edit summary
No edit summary |
No edit summary |
||
| Line 610: | Line 610: | ||
|Gastro-intestinal disturbances (2-20%)), taste disturbances, hepatic disturbances (up to 50%); bradycardia; pulmonary toxicity (1-17%); tremor (9-59%), sleep disorders; hypothyroidism (5-10%), hyperthyroidism (5-10%); reversible corneal microdeposits (up to 98%); phototoxicity, persistent slate-grey skin discoloration (1-7%), injection-site reactions; less commonly onset or worsening of arrhythmia, conduction disturbances, peripheral neuropathy (1-105) and myopathy; very rarely sinus arrest, bronchospasm, ataxia (2-37%), benign intracranial hypertension, headache, vertigo, epididymo-orchitis, impotence, haemolytic or aplastic anaemia, thrombocytopenia, rash, hypersensitivity including photosensitivity (2-20%), anaphylaxis on rapid injection, hypotension (10-30%), respiratory distress syndrome, sweating, and hot flushes | |Gastro-intestinal disturbances (2-20%)), taste disturbances, hepatic disturbances (up to 50%); bradycardia; pulmonary toxicity (1-17%); tremor (9-59%), sleep disorders; hypothyroidism (5-10%), hyperthyroidism (5-10%); reversible corneal microdeposits (up to 98%); phototoxicity, persistent slate-grey skin discoloration (1-7%), injection-site reactions; less commonly onset or worsening of arrhythmia, conduction disturbances, peripheral neuropathy (1-105) and myopathy; very rarely sinus arrest, bronchospasm, ataxia (2-37%), benign intracranial hypertension, headache, vertigo, epididymo-orchitis, impotence, haemolytic or aplastic anaemia, thrombocytopenia, rash, hypersensitivity including photosensitivity (2-20%), anaphylaxis on rapid injection, hypotension (10-30%), respiratory distress syndrome, sweating, and hot flushes | ||
|- | |- | ||
| | |||
|Class IV (Calcium channel blockers) | |Class IV (Calcium channel blockers) | ||
|(See above) | |(See above) | ||
|(See above) | |(See above) | ||
|(See above) | |(See above) | ||
| | |||
|(See above) | |(See above) | ||
|- | |- | ||
| Line 627: | Line 629: | ||
AVRT, poorly tolerated: Class IIIC | AVRT, poorly tolerated: Class IIIC | ||
Since or infrequent AVRT episode(s): Class IIIC | Since or infrequent AVRT episode(s): Class IIIC | ||
Prophylaxis of SVT during pregnancy: Class IC |Gastro-intestinal disturbances (vomiting, diarrhoea, anorexia, abdominal pain) (25%); arrhythmias (up to 50%), AV conduction disturbances (50%); nervous system disturbances (dizziness, apathy, confusion, headache, fatigue, weakness) (25%); blurred or yellow vision; rash, eosinophilia, depression, anorexia, intestinal ischaemia and necrosis, psychosis, gynaecomastia on long-term use, and thrombocytopenia | Prophylaxis of SVT during pregnancy: Class IC | ||
|Gastro-intestinal disturbances (vomiting, diarrhoea, anorexia, abdominal pain) (25%); arrhythmias (up to 50%), AV conduction disturbances (50%); nervous system disturbances (dizziness, apathy, confusion, headache, fatigue, weakness) (25%); blurred or yellow vision; rash, eosinophilia, depression, anorexia, intestinal ischaemia and necrosis, psychosis, gynaecomastia on long-term use, and thrombocytopenia | |||
|- | |- | ||
| | | | ||
| Line 638: | Line 641: | ||
Symptomatic (NYHA class II-IV) HF: Class IIbB | Symptomatic (NYHA class II-IV) HF: Class IIbB | ||
ESC Guidelines Symptomatic (NYHA class II-IV) HF, LVD and AF: Class IB | ESC Guidelines Symptomatic (NYHA class II-IV) HF, LVD and AF: Class IB | ||
Acute HF with AF and VT: Class IC | Acute HF with AF and VT: Class IC | ||
| | |||
|- | |- | ||
|Anti-platelet Drugs | |Anti-platelet Drugs | ||
| Line 671: | Line 675: | ||
| | | | ||
|- | |- | ||
| | | | ||
| | |||
|Clopidogrel | |Clopidogrel | ||
|Prevention of thrombotic events (esp. when warfarin not tolerated) | |Prevention of thrombotic events (esp. when warfarin not tolerated) | ||